Saturday 10 October 2026 Export all AZN data to Excel Powerpack

AstraZeneca PLC

AZN Healthcare Drug Manufacturers General

AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.41%, EPS grew 1.90%, free cash flow fell 107.5% and total debt fell 5.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five; insiders bought in the last twelve months.

159.20 0.42 +0.26%
Market cap
$246.3B
P/E
23.6×
Fwd P/E
23.4×
Dividend yield
2.02%
F-score
9/9
Altman Z
6.26
Beneish M
−2.51
Dividend safety
54/100

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
29,940.00 28,723.00 29,613.00 27,965.00
Total non-current assets
84,516.00 85,351.00 84,402.00 87,868.00
Total Assets
114,456.00 114,074.00 114,015.00 115,833.00
Total current liabilities
34,054.00 30,617.00 32,570.00 31,553.00
Total non-current liabilities
34,431.00 34,738.00 34,061.00 33,910.00
Total liabilities
68,485.00 65,355.00 66,631.00 65,463.00
Common Equity (Total)
45,971.00 48,719.00 47,384.00 50,370.00
Shareholders Equity (Total)
45,971.00 48,719.00 47,384.00 50,370.00
Total Debt
30,874.00 27,819.00 32,030.00 29,491.00

Show all line items

In millions of $ except per-share values · columns are period end dates